Dark

Check out our Level2View

VRP
Invesco Variable Rate Preferred ETF
stock NYSE ETF

Market Open

Oct 2, 2026 3:34:01 PM EDT

23.69USD+0.233%(+0.05)359,542

23.69Bid 23.70Ask 0.01Spread

Pre-market

Sep 30, 2026 8:47:30 AM EDT

23.74USD+0.404%(+0.10)0

After-hours

Oct 1, 2026 4:10:30 PM EDT

23.64USD-0.042%(-0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Mar 16, 2021

04:30PM EDT Invesco Announces Changes to Two ETFs PR Newswire

Feb 18, 2021

02:00AM EST Verona Pharma to Report Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 2, 2021

06:17AM EST In a release issued under the same headline earlier today byVerona Pharma plc(Nasdaq: VRNA),please note that all instances of the unit "g" were mistakenly represented as "mg." The corrected release follows: GlobeNewswire Inc

02:00AM EST Verona Pharma Reports Positive Phase 2 Results with pMDI GlobeNewswire Inc

Jan 14, 2021

02:00AM EST Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed enrollment (n=45) in its pilot clinical study evaluating the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler (pMDI) formulation in U.S. patients hospitalized with COVID-19. GlobeNewswire Inc

Jan 5, 2021

02:00AM EST Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand starting at 8:00 AM ET on Monday, January 11, 2021. GlobeNewswire Inc

Nov 9, 2020

02:00AM EST Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the following virtual investor conferences in November 2020: GlobeNewswire Inc

Oct 29, 2020

03:00AM EDT Verona Pharma plc Operational Update and Financial Results for the GlobeNewswire Inc

Oct 22, 2020

02:00AM EDT Verona Pharma to Announce Interim Results for the Three and Nine GlobeNewswire Inc

Oct 13, 2020

02:00AM EDT Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life GlobeNewswire Inc

Sep 8, 2020

02:00AM EDT Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler (pMDI) formulation in U.S. patients hospitalized with COVID-19. GlobeNewswire Inc

Sep 2, 2020

02:00AM EDT Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on Monday, September 14, 2020 at 5:00 PM ET. GlobeNewswire Inc

Aug 24, 2020

02:00AM EDT Verona Pharma to Present Phase 2b data with Ensifentrine in COPD GlobeNewswire Inc

Aug 19, 2020

02:00AM EDT Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical GlobeNewswire Inc

Aug 14, 2020

02:00AM EDT Verona Pharma plcOperational Update and Financial GlobeNewswire Inc

Aug 3, 2020

02:00AM EDT Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief Financial Officer, will present a company overview at the following virtual investor conferences in August 2020: GlobeNewswire Inc

Jul 30, 2020

02:00AM EDT Verona Pharma to Announce Interim Results for the Three and Six GlobeNewswire Inc

Jul 17, 2020

02:00AM EDT THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (MAR). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. GlobeNewswire Inc

Share